<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02051218</url>
  </required_header>
  <id_info>
    <org_study_id>SAKK 96/12</org_study_id>
    <secondary_id>000000685</secondary_id>
    <secondary_id>2014-001189-87</secondary_id>
    <nct_id>NCT02051218</nct_id>
  </id_info>
  <brief_title>Prevention of Symptomatic Skeletal Events With Denosumab Administered Every 4 Weeks Versus Every 12 Weeks</brief_title>
  <official_title>Prevention of Symptomatic Skeletal Events With Denosumab Administered Every 4 Weeks Versus Every 12 Weeks - A Non-Inferiority Phase III Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Swiss Group for Clinical Cancer Research</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Swiss Group for Clinical Cancer Research</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of the trial is to test the hypothesis that the benefit of denosumab is maintained if&#xD;
      administered only every 12 weeks as compared to every 4 weeks.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Denosumab, a monoclonal antibody against RANK-Ligand has been shown superior to zoledronic&#xD;
      acid in delaying time to a first on-study skeletal related event (SRE) in patients with solid&#xD;
      tumors, with no effects on disease progression or survival. Many SREs were silent compression&#xD;
      fractures found only because of scheduled imaging. The approved dose of denosumab is 120 mg&#xD;
      s.c. every 4 weeks (q4w). Although generally well tolerated, there is a time-dependent&#xD;
      increase in osteonecrosis of the jaw in up to 8% of patients. Cases of fatal hypocalcaemia&#xD;
      were observed during post marketing surveillance.&#xD;
&#xD;
      The optimal dose and schedule for denosumab is unknown. Denosumab is associated with&#xD;
      considerable costs and may add toxicity; thus a study of de-escalation is warranted.&#xD;
&#xD;
      The aim of the trial is to test the hypothesis that the benefit of Denosumab is maintained if&#xD;
      administered 120 mg q12w as compared to 120 mg q4w. The primary endpoint of this open-label&#xD;
      randomized phase III non-inferiority trial is time to first on-trial symptomatic skeletal&#xD;
      event (SSE: i.e. clinically significant pathological fracture, radiation therapy to bone,&#xD;
      surgery to bone or spinal cord compression). With a non-inferiority margin of 1.2 for the&#xD;
      hazard ratio, a power 80% and a type I error 5%, the total sample size is 1380. Secondary&#xD;
      endpoints are safety, time to subsequent on-trial SSE, quality of life, health economic&#xD;
      outcomes, and change in bone turnover markers. This study is open for international&#xD;
      collaboration.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">July 16, 2014</start_date>
  <completion_date type="Anticipated">December 2022</completion_date>
  <primary_completion_date type="Anticipated">December 2021</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Supportive Care</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Time to first on-trial symptomatic skeletal event (SSE; Clinically significant pathological fracture, radiation therapy to bone, surgery to bone or spinal cord compression).</measure>
    <time_frame>at the latest 5 years after randomization.</time_frame>
    <description>A SSE is defined as one of the following events: Clinically significant pathological fracture, radiation therapy to bone, surgery to bone, or spinal cord compression.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Toxicity (focus on hypocalcaemia and osteonecrosis of the jaw)</measure>
    <time_frame>at the latest 5 years after randomization.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to first and subsequent on-trial SSE</measure>
    <time_frame>at the latest 5 years after randomization.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of Life measured by FACT-G and FACT-BP</measure>
    <time_frame>at the latest 5 years after randomization.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Skeletal morbidity period rate (SMPR)</measure>
    <time_frame>at the latest 5 years after randomization.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Skeletal morbidity rate (SMR)</measure>
    <time_frame>at the latest 5 years after randomization.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Health economic analysis</measure>
    <time_frame>at the latest 5 years after randomization.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Bone turnover markers</measure>
    <time_frame>at the latest 5 years after randomization.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Survival (OS)</measure>
    <time_frame>at the latest 5 years after randomization.</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">1181</enrollment>
  <condition>Metastatic Breast Cancer</condition>
  <condition>Metastatic Prostate Cancer</condition>
  <condition>Bone Metastases</condition>
  <arm_group>
    <arm_group_label>Arm A (standard arm)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Denosumab 120mg (XGEVA®) sc. q4w</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm B (reduced arm)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Denosumab 120mg (XGEVA®) sc. q4w [weeks 1, 5, 9] followed by Denosumab 120mg (XGEVA®) sc. q12w [weeks 13, 25, …]</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Denosumab (reduced dosing)</intervention_name>
    <description>3x Denosumab 120mg (XGEVA®) sc. q4w followed by Denosumab 120mg (XGEVA®) sc. q12w</description>
    <arm_group_label>Arm B (reduced arm)</arm_group_label>
    <other_name>XGEVA®</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Denosumab (standard dosing)</intervention_name>
    <description>Denosumab 120mg (XGEVA®) sc. q4w</description>
    <arm_group_label>Arm A (standard arm)</arm_group_label>
    <other_name>XGEVA®</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patient has given written informed consent.&#xD;
&#xD;
          -  Histologically confirmed diagnosis of breast or prostate cancer before randomization.&#xD;
&#xD;
          -  Patient has metastatic breast cancer (stage IV, all subtypes allowed) or prostate&#xD;
             cancer (stage IV) and bone metastases and is planned to receive or is receiving&#xD;
             antineoplastic treatment.&#xD;
&#xD;
          -  Patients with prostate cancer must have evidence of disease progression on continuous&#xD;
             androgen deprivation therapy (CRPC).&#xD;
&#xD;
          -  Patients must have ≥ 3 bone metastases (lytic or blastic or mixed). The lesions must&#xD;
             be documented by radiological evaluation within 12 weeks before randomization (by&#xD;
             X-Ray, CT scan, PET-CT, MRI scan or bone scintigraphy).&#xD;
&#xD;
          -  WHO performance status 0-2&#xD;
&#xD;
          -  Age ≥ 18 years.&#xD;
&#xD;
          -  Corrected serum calcium ≥ 2 mmol/l and ≤ 3 mmol/l (medical treatments to obtain serum&#xD;
             calcium levels in the normal range are allowed, as far as no denosumab is used.&#xD;
             Maximally 1 dose of bisphosphonates in the case of hypercalcemia is allowed, if the&#xD;
             bisphosphonate was applied at least 3 weeks before the first dose of denosumab).&#xD;
&#xD;
          -  Liver transaminases not more than 1.5 x ULN or not more than 3 x ULN with liver&#xD;
             metastases. Serum total bilirubin ≤ 1.5 x ULN (≤ 2.0 x ULN in case of known Gilbert's&#xD;
             disease)&#xD;
&#xD;
          -  Women are not breastfeeding. Women with child-bearing potential are using effective&#xD;
             contraception, are not pregnant and agree not to become pregnant during participation&#xD;
             in the trial and during the 12 months thereafter. A negative pregnancy test before&#xD;
             inclusion (within 7 days) into the trial is required for all women with child-bearing&#xD;
             potential.&#xD;
&#xD;
          -  Men agree not to father a child during participation in the trial and during 12 months&#xD;
             thereafter.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Definite contraindication for denosumab (e.g. hypocalcaemia [Albumin-corrected serum&#xD;
             calcium &lt; 2.0 mmol/l]).&#xD;
&#xD;
          -  History or current evidence of osteonecrosis of the jaw.&#xD;
&#xD;
          -  Non-healed mucosa in oral cavity (by surgery or as a side effect of any other&#xD;
             treatment).&#xD;
&#xD;
          -  Jaw or dental conditions that require oral surgery or if surgery or invasive dental&#xD;
             procedures are planned.&#xD;
&#xD;
          -  Prior use of denosumab for bone metastases (dose 120 mg every 4 weeks) or&#xD;
             bisphosphonates to treat bone metastases. Patients treated with denosumab or&#xD;
             bisphosphonates against osteopenia or osteoporosis are allowed to enter the trial if&#xD;
             the last dose was more than 28 days before randomization.&#xD;
&#xD;
          -  Patients with known osteoporosis (T-score ≤ -2.5) at study entry (since fractures from&#xD;
             osteoporosis are difficult to be discriminated from fractures through bone&#xD;
             metastases).&#xD;
&#xD;
          -  Radiotherapy or surgery to the bone within the last two weeks before randomization or&#xD;
             planned within 6 weeks after randomization.&#xD;
&#xD;
          -  Presence or history of CNS metastases or leptomeningeal disease. A MRI evaluation&#xD;
             within 12 weeks before randomization must be performed in case of suspicious symptoms.&#xD;
&#xD;
          -  Psychiatric disorder precluding understanding of information on trial related topics,&#xD;
             giving informed consent, filling out QoL forms.&#xD;
&#xD;
          -  Concurrent treatment in a clinical trial with SSE or SRE as primary endpoint.&#xD;
&#xD;
          -  Known hypersensitivity to trial drug or hypersensitivity to any other component of the&#xD;
             trial drug (e.g. fructose).&#xD;
&#xD;
          -  Any concomitant drugs contraindicated for use with the trial drugs according to the&#xD;
             approved product information.&#xD;
&#xD;
          -  Any psychological, familial, sociological or geographical condition potentially&#xD;
             hampering compliance with the trial protocol.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Roger von Moos, PD MD</last_name>
    <role>Study Chair</role>
    <affiliation>Kantonsspital Graubünden</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Arnoud Templeton, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Cantonal Hospital of St. Gallen</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Silke Gillessen, Prof</last_name>
    <role>Study Chair</role>
    <affiliation>Cantonal Hospital of St. Gallen</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Andreas Müller, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Kantonsspital Winterthur KSW</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Landeskrankenhaus Feldkirch</name>
      <address>
        <city>Feldkirch</city>
        <zip>6800</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Klinikum Wels-Grieskrichen GmbH</name>
      <address>
        <city>Wels</city>
        <zip>4600</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Uniklinik Düsseldorf, Urologische Klinik</name>
      <address>
        <city>Düsseldorf</city>
        <zip>40225</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Düsseldorf, Frauenheilkunde/Geburtshilfe</name>
      <address>
        <city>Düsseldorf</city>
        <zip>40225</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitätsmedizin Göttingen</name>
      <address>
        <city>Göttingen</city>
        <zip>37075</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Schleswig-Holstein</name>
      <address>
        <city>Lübeck</city>
        <zip>23538</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitäts-Frauenklinik Ulm</name>
      <address>
        <city>Ulm</city>
        <zip>89075</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hirslanden Klinik Aarau</name>
      <address>
        <city>Aarau</city>
        <zip>CH-5001</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kantonspital Aarau</name>
      <address>
        <city>Aarau</city>
        <zip>CH-5001</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kantonsspital Baden</name>
      <address>
        <city>Baden</city>
        <zip>CH-5404</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitaetsspital Basel</name>
      <address>
        <city>Basel</city>
        <zip>4031</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Brustzentrum Basel - Praxis für ambulante Tumortherapie</name>
      <address>
        <city>Basel</city>
        <zip>4052</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. Claraspital AG</name>
      <address>
        <city>Basel</city>
        <zip>CH-4016</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Istituto Oncologico della Svizzera Italiana - Ospedale Regionale Bellinzona e Valli</name>
      <address>
        <city>Bellinzona</city>
        <zip>6500</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Klinik Engeried / Praxis Oncocare</name>
      <address>
        <city>Bern</city>
        <zip>3012</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Inselspital, Bern</name>
      <address>
        <city>Bern</city>
        <zip>CH-3010</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Spitalzentrum Biel</name>
      <address>
        <city>Biel</city>
        <zip>CH-2501</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Spitalzentrum Oberwallis</name>
      <address>
        <city>Brig</city>
        <zip>3900</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kantonsspital Graubünden</name>
      <address>
        <city>Chur</city>
        <zip>7000</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre du Sein de Genève, Clinique des Grangettes</name>
      <address>
        <city>Chêne-Bougeries</city>
        <zip>1224</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kantonsspital Frauenfeld - Brustzentrum</name>
      <address>
        <city>Frauenfeld</city>
        <zip>8501</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hopital Fribourgeois</name>
      <address>
        <city>Fribourg</city>
        <zip>1708</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinique De Genolier</name>
      <address>
        <city>Genolier</city>
        <zip>1272</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hopitaux Universitaires de Geneve</name>
      <address>
        <city>Genève 14</city>
        <zip>1211</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hôpital neuchâtelois</name>
      <address>
        <city>La Chaux-de-Fonds</city>
        <zip>2300</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CCAC Lausanne</name>
      <address>
        <city>Lausanne</city>
        <zip>1004</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHUV</name>
      <address>
        <city>Lausanne</city>
        <zip>1011</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kantonsspital Liestal</name>
      <address>
        <city>Liestal</city>
        <zip>CH-4410</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Fondazione Oncologia / Oncologia ematologia</name>
      <address>
        <city>Locarno</city>
        <zip>6600</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Oncologia Varini &amp; Calderoni &amp; Christinat</name>
      <address>
        <city>Lugano</city>
        <zip>6900</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Luzerner Kantonsspital</name>
      <address>
        <city>Luzern</city>
        <zip>6000</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hirslanden Klinik St. Anna Luzern</name>
      <address>
        <city>Luzern</city>
        <zip>6006</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Onkologie Zentrum Spital Männedorf</name>
      <address>
        <city>Männedorf</city>
        <zip>8708</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kantonsspital Muensterlingen</name>
      <address>
        <city>Münsterlingen</city>
        <zip>8596</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kantonsspital Olten</name>
      <address>
        <city>Olten</city>
        <zip>4600</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Rundum Onkologie am Bahnhofpark</name>
      <address>
        <city>Sargans</city>
        <zip>7320</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Spital Limmattal</name>
      <address>
        <city>Schlieren</city>
        <zip>8952</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hôpital du Valais Sion</name>
      <address>
        <city>Sion</city>
        <zip>1951</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Bürgerspital Solothurn - Onkologiezentrum</name>
      <address>
        <city>Solothurn</city>
        <zip>4600</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Brustzentrum Ostschweiz</name>
      <address>
        <city>St. Gallen</city>
        <zip>9016</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Zentrum fuer Tumordiagnostikund Praevention</name>
      <address>
        <city>St. Gallen</city>
        <zip>CH-9006</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kantonsspital St. Gallen</name>
      <address>
        <city>St. Gallen</city>
        <zip>CH-9007</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Spital STS AG</name>
      <address>
        <city>Thun</city>
        <zip>3600</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kantonsspital Winterthur</name>
      <address>
        <city>Winterthur</city>
        <zip>8401</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Onkologie Bellevue</name>
      <address>
        <city>Zurich</city>
        <zip>8001</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Onkozentrum Klinik im Park</name>
      <address>
        <city>Zurich</city>
        <zip>8038</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Brustzentrum-Zürich</name>
      <address>
        <city>Zürich</city>
        <zip>8005</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hirslanden Onkozentrum Zürich</name>
      <address>
        <city>Zürich</city>
        <zip>8032</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitätsspital Zürich</name>
      <address>
        <city>Zürich</city>
        <zip>8091</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Stadtspital Triemli</name>
      <address>
        <city>Zürich</city>
        <zip>CH-8063</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Austria</country>
    <country>Germany</country>
    <country>Switzerland</country>
  </location_countries>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>January 29, 2014</study_first_submitted>
  <study_first_submitted_qc>January 29, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 31, 2014</study_first_posted>
  <last_update_submitted>October 15, 2021</last_update_submitted>
  <last_update_submitted_qc>October 15, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 18, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>metastatic breast cancer</keyword>
  <keyword>castration resistant metastatic prostate cancer</keyword>
  <keyword>bone metastases</keyword>
  <keyword>Denosumab</keyword>
  <keyword>XGEVA</keyword>
  <keyword>de-escalation</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prostatic Neoplasms</mesh_term>
    <mesh_term>Neoplasm Metastasis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Denosumab</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

